Reference : Hepatitis C genotype 4 response rate to pegylated interferon and ribavirin treatment in ...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
http://hdl.handle.net/2268/66616
Hepatitis C genotype 4 response rate to pegylated interferon and ribavirin treatment in Belgium is similar to genotype 1
English
de Galocsy, C. [ > > ]
Kaufman, L. [ > > ]
Tomasovic, S. [ > > ]
Delwaide, Jean mailto [Université de Liège - ULg > > Gastro-Entérologie-Hépatologie >]
Nevens, F. [ > > ]
2010
Acta Gastro-Enterologica Belgica
Acta Medica Belgica
73
229-234
Yes (verified by ORBi)
International
0001-5644
Bruxelles
Belgique
[en] Hepatitis C, genotype 4, genotype 1, treatment, Pegylated
[en] Background and aims : Patients with genotype 4 (G4) chronic
hepatitis C from the Middle East respond better to treatment than
genotype 1 (G1) patients. There are few data on the response rates
to treatment of G4 patients living in Western Europe. Many G4
patients in Belgium originate from Central Africa, and their
response to treatment seems lower.
Methods : We analysed the data from 2 randomized phase III
studies conducted in Belgium, BerNar-1 and BerNar-2, comparing
the sustained virological response (SVR) to pegylated interferon
and ribavirin of 78 G4 patients (34 Caucasians, 44 Blacks) and 477
G1 patients (455 Caucasians, 12 Blacks), and assessing the predictors
of SVR.
Results : Baseline characteristics of G4 and G1 patients were
similar except mainly for race. Complete early virological response
(cEVR) was similar in G4 (73.2%) and G1 (68.1%). cEVR was
also similar between Black and Caucasian G4 and between Black
and Caucasian G1 patients. Partial early virological response was
similar for G4 and G1. SVR was similar for G4 (51.3%) and G1
(51.8%). There was a trend for a higher SVR in Caucasians than in
Blacks. In multivariate analysis, the only predictors for SVR were
the presence of cirrhosis, HCV viral load, age < 40 vs 40 yrs, and
treatment status (relapsers vs naïve).
Conclusions : G4 patients in Belgium have the same SVR as G1
patients. It is lower than the SVR described in Arab countries,
especially for Black G4 patients. (Acta gastro enterol. belg., 2010, 73,
229-234).
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/66616

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Génotype 4 de Galocsy et al.pdfPublisher postprint223.48 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.